International Multicenter Retrospective Study of Spindle Cell/Sclerosing Rhabdomyosarcoma: A PUSH Consortium Study

We report clinical outcomes of patients with localized and advanced spindle cell/sclerosing rhabdomyosarcoma (S-RMS) from the Pushing Ultra-Rare Sarcomas Towards Hope (PUSH) consortium, an international collaborative network. Clinical data from patients with molecularly confirmed S-RMS treated at 25 institutions between January 2013 and December 2023 were reviewed. Endpoints included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and overall response rate (ORR). Univariate analyses were performed. Sixty-four patients were identified. The most common molecular alteration was MYOD1 p.L122R mutation (56%). Among patients with localized S-RMS (n=42), the 3-year OS and DFS rates were 61.2% and 34.2%, respectively. Local recurrence was more frequent than distant metastasis (14 vs. 8). Tumor size was significantly associated with DFS (P=0.008) and distant metastasis (P=0.012). Among patients with advanced S-RMS (n=37), median OS was 14.8 months (95% CI: 10.1-28.0), with 26.2% alive at 2 years. Lung metastasis was associated with worse OS (HR=4.07, P=0.004). Twenty-nine patients (78%) received first-line chemotherapy, most commonly anthracycline-based treatment (48%). The median PFS was 5.4 months (95% CI: 3.7-12.0), and evaluable ORR was 24% (6/25). The evaluable ORR was 27% in MYOD1-altered and 22% in TFCP2-altered patients across all treatment lines. These findings suggest that ∼one-third of patients with completely resected localized S-RMS may be cured. The predominance of local recurrence highlights the need to optimize locoregional management. Advanced S-RMS has a poor prognosis, and conventional systemic therapies provide limited benefit, underscoring the urgent need for novel treatments.

Authors

Institutions

Publication Details

Journal
The American Journal of Surgical Pathology
Published
2026-11-19
DOI
https://doi.org/10.1097/pas.0000000000002639
Primary Topic
Sarcoma Diagnosis and Treatment
Type
article
Field-Weighted Citation Impact
0.00
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
article

International Multicenter Retrospective Study of Spindle Cell/Sclerosing Rhabdomyosarcoma: A PUSH Consortium Study

Andrea Napolitano, Daniel Wong, Anna Mariuk-Jarema, Ryan A. Denu et al.
The American Journal of Surgical Pathology
Sarcoma Diagnosis and Treatment
article

International Multicenter Retrospective Study of Spindle Cell/Sclerosing Rhabdomyosarcoma: A PUSH Consortium Study

Andrea Napolitano, Daniel Wong, Anna Mariuk-Jarema, Ryan A. Denu, Ruben Jaeger, Daniel S. Lefler, Silva Ljevar, Angelo Paolo Dei Tos, Ilkyu Han, Gabriel Tinoco, Jessica L. Davis, William Tap, Rosalba Miceli, Ingrid M.E. Desar, Roberto Scanferla, Alexander J. Lazar, Vivek A. Bhadri, Lorenzo D’Ambrosio, Tom Wei‐Wu Chen, Silvia Stacchiotti, Claudia Giani, Giacomo Giulio Baldi, Philippos Apolinário Costa, Silvia Taverna, Daniel Jack Reinhorn, Marta Sbaraglia, Valerie Shiwen Yang, Susie Bae, Judith V.M.G. Bovée, Michael S. Nakazawa, Cristina R. Antonescu, Inga‐Marie Schaefer, Boris Itkin, Miguel Henriques Abreu, Elizabeth M. Connolly, Xiaolan Feng, Toni Ibrahim, Alessandro Gronchi, Ana Sebio, Mauricio F. Ribeiro, Ajay Gupta
article en

Abstract

We report clinical outcomes of patients with localized and advanced spindle cell/sclerosing rhabdomyosarcoma (S-RMS) from the Pushing Ultra-Rare Sarcomas Towards Hope (PUSH) consortium, an international collaborative network. Clinical data from patients with molecularly confirmed S-RMS treated at 25 institutions between January 2013 and December 2023 were reviewed. Endpoints included overall survival (OS), disease-free survival (DFS), progression-free survival (PFS), and overall response rate (ORR). Univariate analyses were performed. Sixty-four patients were identified. The most common molecular alteration was MYOD1 p.L122R mutation (56%). Among patients with localized S-RMS (n=42), the 3-year OS and DFS rates were 61.2% and 34.2%, respectively. Local recurrence was more frequent than distant metastasis (14 vs. 8). Tumor size was significantly associated with DFS (P=0.008) and distant metastasis (P=0.012). Among patients with advanced S-RMS (n=37), median OS was 14.8 months (95% CI: 10.1-28.0), with 26.2% alive at 2 years. Lung metastasis was associated with worse OS (HR=4.07, P=0.004). Twenty-nine patients (78%) received first-line chemotherapy, most commonly anthracycline-based treatment (48%). The median PFS was 5.4 months (95% CI: 3.7-12.0), and evaluable ORR was 24% (6/25). The evaluable ORR was 27% in MYOD1-altered and 22% in TFCP2-altered patients across all treatment lines. These findings suggest that ∼one-third of patients with completely resected localized S-RMS may be cured. The predominance of local recurrence highlights the need to optimize locoregional management. Advanced S-RMS has a poor prognosis, and conventional systemic therapies provide limited benefit, underscoring the urgent need for novel treatments.

The American Journal of Surgical Pathology
Brigham and Women's Hospital (US), Roswell Park Comprehensive Cancer Center (US), Memorial Sloan Kettering Cancer Center (US), The University of Texas MD Anderson Cancer Center (US), Harvard University (US), University of Padua (IT), University of Calgary (CA), The University of Western Australia (AU), Leiden University Medical Center (NL), Peter MacCallum Cancer Centre (AU), Hospital de Sant Pau (ES), Seoul National University Hospital (KR), Radboud University Medical Center (NL), The Netherlands Cancer Institute (NL), Moffitt Cancer Center (US), Yale University (US), Queen Elizabeth II Medical Centre (AU), Chris O’Brien Lifehouse (AU), University Hospital of Zurich (CH), Cancer Research And Biostatistics (US), IPO Porto (PT), Azienda Ospedaliero-Universitaria Careggi (IT), Royal Marsden Hospital (GB), Istituto Ortopedico Rizzoli (IT), National Taiwan University Hospital (TW), National Cancer Centre Singapore (SG), The Maria Sklodowska-Curie National Research Institute of Oncology (PL), Center for Clinical Research (United States) (US), Azienda Usl Toscana Centro (IT), Fondazione IRCCS Istituto Nazionale dei Tumori (IT), Pathwest Laboratory Medicine (AU), Hospital of Prato (IT), Indiana University School of Medicine (US), Sultan Qaboos Comprehensive Cancer Care & Research Center (OM), Sultan Qaboos University (OM), The Ohio State University (US), University of Turin (IT), University of Pennsylvania (US)
Sarcoma Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon